Truist Securities Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $35

Truist Securities has upgraded Tandem Diabetes Care (NASDAQ: TNDM) from a Hold to a Buy rating. The price target for the stock has been increased from $27 to $35.